ES2490613T3 - ARMET como marcador de cáncer - Google Patents

ARMET como marcador de cáncer Download PDF

Info

Publication number
ES2490613T3
ES2490613T3 ES09798890.1T ES09798890T ES2490613T3 ES 2490613 T3 ES2490613 T3 ES 2490613T3 ES 09798890 T ES09798890 T ES 09798890T ES 2490613 T3 ES2490613 T3 ES 2490613T3
Authority
ES
Spain
Prior art keywords
cancer
armet
phase
sample
cancer marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09798890.1T
Other languages
English (en)
Inventor
Markus Roessler
Johann Karl
Michael Tacke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2490613T3 publication Critical patent/ES2490613T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un método para evaluar el cáncer de pulmón, cáncer de colon, cáncer de mama o cáncer de ovario in vitro, que comprende medir en una muestra la concentración de: (a) proteína ARMET (rica en arginina, mutada en tumores en fase tempranas) y/o fragmentos de la misma. (b) opcionalmente uno o más marcadores adicionales de cáncer, y (c) usar el resultado de la medición de la fase (a) y opcionalmente de la fase (b) en la evaluación del cáncer, donde dicha muestra es suero o plasma, y donde un incremento de la concentración de una proteína ARMET y/o fragmentos de la misma es indicativo de cáncer de pulmón, cáncer de colon, cáncer de mama o cáncer de ovario

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
Análisis por LC-ESI-MSMS:
La digestión tríptica (100 µl) se separa mediante una HPLC bidimensional (MudPIT) en un sistema Nano-LC (Ultimate, Famos, Switchos; LC Packings, Idstein, Alemania). La separación se realiza con columnas bidimensionales 5 auto-empaquetadas (Sílice fundida: PicoFrit 75 µm, New Objective; RP: ProntoSil 120-5-C18 AQ+, Bischoff; SCX: Partisil 10, Whatman). Se generan 11 fracciones SCX mediante la elución en fases con cantidades crecientes sucesivamente de NH4Ac (de 0 a 1.500 mM). Estas se separan posteriormente en la parte RP de la columna y se analizan en línea usando escaneos dependientes de datos con una trampa de iones ESI-MS (LCQ deca XP; Thermo Electron, Massachusetts, E.E.U.U.; véanse los parámetros en la tabla X). Para cada muestra se realizan tres series.
10 Los datos brutos se procesan con un sistema no comercial de manejo de datos propio de Roche que usa Sequest como algoritmo de base (véase los parámetros en la Tab. X). Se combinaron las listas resultantes de péptidos identificados y proteínas de las series de réplicas.
La proteína ARMET se identifica con ayuda de las secuencias identificadas y que se dan en la Tab. 2. 15 Detección de ARMET como un marcador potencial de cáncer de pulmón:
Para cada paciente, se comparan las proteínas identificadas y el número de péptidos correspondientes de la muestra del tumor con los resultados que corresponden del tejido adyacente normal. De esta manera, se descubre que la 20 proteína ARMET está presente específicamente o es muy abundante en tejido tumoral y no es detectable o es difícilmente detectable en el tejido sano control.
Tabla 1: Adquisición de datos por MSMS y parámetros de búsqueda de bases de datos
Adquisición de datos por MSMS
Exclusión MS 350-2000 Da para iones precursores
Recuento de repeticiones
2
Duración de la repetición
0,25 min
Tamaño de lista de exclusión
50
Duración de la exclusión
5 min
Amplitud de la masa de exclusión
bajo 0,5 Da, alto 1,5 Da
Sequest
Número de iones 30
Intensidad mínima de los iones
10.000 unidades
Tolerancia de masa del precursor
1,5 Da
Tolerancia de masa del fragmento
1,5 Da
Xcorr
>1,8; 2,3, 2,8 (z = 1; 2; 3)
dCn
> 0,1
Sp
> 500
Bases de datos
Humangp (ensamblada por Roche Bioinformatics)
25 La proteína ARMET está fuertemente sobre-representada en tejido tumoral de pacientes que padecen cáncer de pulmón. Las siguientes secuencias peptídicas de la proteína ARMET se identifican mediante la búsqueda en el formulario de la base de datos “LCQ-MS2-data” en tejido tumoral:
Usando el método descrito anteriormente se han identificado las siguientes secuencias derivadas de ARMET. 30 Tabla 2: Secuencias identificadas por ESI-MSMS
Secuencia identificada
Tramo de aminoácidos de ARMET (cf. SEC ID Nº: 1)
• DRDVTFSPATIENELIK
• 43-59
• DVTFSPATIENELIK
• 45-59
• IINEVSKPLAHHIPVEK
• 85-101
• LCYYIGATDDAATK
• 71-84
17
imagen16
imagen17
imagen18
imagen19

Claims (1)

  1. imagen1
ES09798890.1T 2008-12-22 2009-12-18 ARMET como marcador de cáncer Active ES2490613T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08022238 2008-12-22
EP08022238 2008-12-22
PCT/EP2009/009159 WO2010072383A1 (en) 2008-12-22 2009-12-18 Armet as a marker for cancer

Publications (1)

Publication Number Publication Date
ES2490613T3 true ES2490613T3 (es) 2014-09-04

Family

ID=40474747

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09798890.1T Active ES2490613T3 (es) 2008-12-22 2009-12-18 ARMET como marcador de cáncer

Country Status (7)

Country Link
US (3) US8741587B2 (es)
EP (1) EP2380024B1 (es)
JP (1) JP5368579B2 (es)
CN (1) CN102317784B (es)
CA (1) CA2747942C (es)
ES (1) ES2490613T3 (es)
WO (1) WO2010072383A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102375057A (zh) * 2010-08-10 2012-03-14 复旦大学 一种均相荧光同时检测多种血清标志物的方法
WO2012123296A1 (en) * 2011-03-11 2012-09-20 Roche Diagnostics Gmbh Armet as marker for chronic obstructive pulmonary disease (copd)
KR20140121449A (ko) * 2012-01-24 2014-10-15 유니버시티 오브 매사추세츠 췌장 베타-세포 장애에서의 가용성 ｍａｎｆ
NZ703411A (en) 2012-06-27 2017-09-29 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
JP6652916B2 (ja) * 2013-06-20 2020-02-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 膵臓がんを診断するための方法
EP3022561B1 (en) * 2013-07-15 2019-08-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for the prognosis of survival time of a patient suffering from a solid cancer
CN104677998A (zh) * 2013-11-29 2015-06-03 沈阳药科大学 血浆评估肺癌的生物标记物
CA2943254C (en) * 2014-03-24 2021-05-04 Instrumentation Laboratory Company Bioassay system and method for detecting analytes in body fluids
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
WO2015200469A1 (en) * 2014-06-24 2015-12-30 University Of Massachusetts Manf as a regulator of immune system function
SG10202012249YA (en) 2014-12-08 2021-01-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
CN105717147B (zh) * 2016-03-29 2018-11-23 复旦大学附属中山医院 一种基于ct影像及生物标志物谱针对中国城市人口肺结节人群的肺癌风险预测试剂盒
CN105891482B (zh) * 2016-03-29 2017-12-19 复旦大学附属中山医院 一种基于生物标志物谱针对中国农村人口肺结节人群的肺癌风险预测模型
WO2017201225A1 (en) * 2016-05-19 2017-11-23 Poc Medical Systems, Inc. Cancer screening via detection and quantification of multiple biomarkers
CN106645725B (zh) * 2017-01-06 2018-07-24 安徽医科大学 基于manf作为标记物的肝细胞肝癌和肝内胆管细胞癌鉴别产品及方法
CN117173083A (zh) * 2022-07-22 2023-12-05 浙江省肿瘤医院 基于舌象图像和肿瘤标志物的肿瘤预测系统、方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
ATE370414T1 (de) 2002-12-20 2007-09-15 Hoffmann La Roche Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
JP2006526405A (ja) * 2003-06-04 2006-11-24 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 示差的調節された肝細胞癌遺伝子およびその利用

Also Published As

Publication number Publication date
WO2010072383A1 (en) 2010-07-01
JP2012513016A (ja) 2012-06-07
CA2747942C (en) 2016-12-06
US20160377625A1 (en) 2016-12-29
WO2010072383A8 (en) 2010-12-29
US20110212465A1 (en) 2011-09-01
US8741587B2 (en) 2014-06-03
US20140219998A1 (en) 2014-08-07
CN102317784B (zh) 2014-07-16
EP2380024A1 (en) 2011-10-26
CA2747942A1 (en) 2010-07-01
JP5368579B2 (ja) 2013-12-18
EP2380024B1 (en) 2014-06-11
CN102317784A (zh) 2012-01-11

Similar Documents

Publication Publication Date Title
ES2490613T3 (es) ARMET como marcador de cáncer
Klammer et al. Phosphosignature predicts dasatinib response in non-small cell lung cancer
US20040005634A1 (en) System and method for determining differential protein expression, diagnostic biomarker discovery system and method of using the same, and protein biomarkers and therapeutic and diagnostic uses thereof
Grosstessner-Hain et al. Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome
KR101645841B1 (ko) 인간 폐조직 병변의 지표가 되는 인간 혈청 내 단백질의 동정
RU2015126651A (ru) Способы скрининга
Wanner et al. Proteomic profiling and functional characterization of early and late shoulder osteoarthritis
Matsumoto et al. A proteomic approach for the diagnosis of ‘Oketsu’(blood stasis), a pathophysiologic concept of Japanese traditional (Kampo) medicine
Mehus et al. Quantitation of human metallothionein isoforms: a family of small, highly conserved, cysteine-rich proteins
Mustafa et al. Identification of glioma neovascularization-related proteins by using MALDI-FTMS and nano-LC fractionation to microdissected tumor vessels
Saafan et al. Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer–proof of concept towards a systems pharmacology approach
Kang et al. A proteomic approach to understand the clinical significance of acute myeloid Leukemia–derived extracellular vesicles reflecting essential characteristics of Leukemia
Liu et al. Serum peptidome profiling analysis for the identification of potential biomarkers in cervical intraepithelial neoplasia patients
TW201734455A (zh) 一種用以診斷及預斷癌症的方法
Lukic et al. An integrated approach for comparative proteomic analysis of human bile reveals overexpressed cancer-associated proteins in malignant biliary stenosis
Liu et al. Decreased serum levels of nucleolin protein fragment, as analyzed by bead-based proteomic technology, in multiple sclerosis patients compared to controls
Townsend et al. CycLS: Accurate, whole-library sequencing of cyclic peptides using tandem mass spectrometry
CN111381042B (zh) 肝细胞癌中大血管侵犯的预测方法、试剂盒及其应用
KR20240025222A (ko) 질량분석법 기반의 간세포암 조기 진단용 바이오마커 패널
Bao et al. Isolation and structural identification of a new T1-conotoxin with unique disulfide connectivities derived from Conus bandanus
Picou et al. Analysis of Aβ (1-40) and Aβ (1-42) monomer and fibrils by capillary electrophoresis
Faktor et al. Identification and characterisation of pro-metastatic targets, pathways and molecular complexes using a toolbox of proteomic technologies
Li et al. Antibody-free enrichment method for proteome-wide analysis of endogenous SUMOylation sites
Min et al. Label-free quantitative proteomics and N-terminal analysis of human metastatic lung cancer cells
Crugliano et al. Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation